1. Serum interleukin-12 levels in patients with multiple sclerosis
- Author
-
Dusan Popadic, Zvonimir Lević, Jelena Drulovic, Vera Pravica, Marija Mostarica-Stojkovic, Nebojsa Stojsavljevic, and Sarlota Mesaros
- Subjects
Adult ,Male ,Multiple Sclerosis ,medicine.medical_treatment ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Immunopathology ,medicine ,Humans ,Autoimmune disease ,business.industry ,General Neuroscience ,Multiple sclerosis ,Interleukin ,medicine.disease ,Interleukin-12 ,3. Good health ,Cytokine ,Immunology ,Interleukin 12 ,Female ,Tumor necrosis factor alpha ,business ,030217 neurology & neurosurgery ,030215 immunology - Abstract
Increasing body of evidence which suggests a crucial role for interleukin (IL)-12 in modulating immune responses in multiple sclerosis (MS) prompted us to analyze IL-12 in serum from MS patients. We measured the sera concentrations of IL-12, tumor necrosis factor (TNF)-alpha and transforming growth factor-beta1, in 21 MS patients and 13 patients with non-inflammatory nervous diseases. In clinically active MS, serum levels of IL-12 were detectable in 53% and TNF-alpha in 40% of patients. None of the patients with clinically inactive MS had detectable IL-12 and TNF-alpha sera levels. Analysis of serum concentrations of all three cytokines revealed no significant differences between MS patients and controls. These findings provide further evidence that both IL-12 and TNF-alpha might have an active role in immunopathogenesis of MS.
- Published
- 1998
- Full Text
- View/download PDF